BIOIMAGING

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目及 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 该核心旨在提供定量磁共振成像（MRI）、体积局部光谱（MRS）、光谱成像（MRSI）和单光子发射计算机断层扫描（SPECT），用于细胞和纳米材料生物分布和治疗功效的体内测定。项目支持包括纳米材料分布的药代动力学测量（项目1-4），超顺磁性氧化铁标记细胞（项目3）和纳米材料（提高灵敏度和空间分辨率的替代方法，项目1，3，4）的T2* 加权成像或γ标记纳米颗粒（项目1，3，4）和细胞（项目1）的SPECT。 将通过使用T1和T2加权MRI（项目3、4）观察肿瘤大小、使用自旋标记灌注MRI（项目4）观察肿瘤灌注以及通过31 P MRS（未来开发、项目3、4和未来肿瘤纳米材料开发项目）早期确定药物疗效，对疾病进展和治疗结局进行无创监测。 将使用定量水抑制质子磁共振光谱成像（1H MRSI）监测神经元活力、神经毒性和/或疾病进展（项目1、2、3）。 虽然划分是为了将核心结构分为药物监测和疾病监测，但目标是根据技术方法划分的。 这样做的目的是最好地说明如何利用核心及其重要的技术资源。 显然，执行SPECT、各种定量MRI方法、1H MRSI和31 P MRS以支持纳米医学中广泛的研究活动的能力是该提议的关键优势。 该核心将提供精确定义药物生物分布、摄取动力学的能力，为基于靶向纳米颗粒的新型造影剂的开发提供支持，重要的是，纳米材料药物递送对疾病结局的影响。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This core is designed to provide quantitative magnetic resonance imaging (MRI), volume localized spectroscopy (MRS), spectroscopic imaging (MRSI) and single photon emission computed tomography (SPECT) for in-vivo assays of cell and nanomaterial biodistribution and treatment efficacy. Project support includes pharmacokinetic measures of nanomaterial distribution (Projects 1-4), T2* weighted imaging of superparamagnetic iron oxide labeled cells (Project 3) and nanomaterials (alternate method for improved sensitivity and spatial resolution, Projects 1, 3, 4) or SPECT of gamma labeled nanoparticles (Projects 1, 3, 4) and cells (Project 1). Non-invasive monitoring of disease progression and therapeutic outcomes will be provided by observing tumor size using T1 and T2 weighted MRI (Projects 3,4), tumor perfusion using spin tagged perfusion MRI (Project 4), and early determination of drug efficacy by 31P MRS (Future development, Projects 3,4 and future tumor nanomaterial development projects). Monitoring neuronal viability, neurotoxicity, and/or disease progression will be accomplished using quantitative water-suppressed proton magnetic resonance spectroscopic imaging (1H MRSI) (Projects 1, 2, 3). Although the divisions were made to separate the core structures into drug and disease monitoring, the aims are divided based on technical approaches. This was done with the goals of best describing how the core and its significant technical resources will be utilized. Clearly, the abilities to perform SPECT, a variety of quantitative MRI methods, 1H MRSI, and 31P MRS to support broad based research activities in nanomedicine are critical strengths of this proposal. This core will provide abilities to precisely define drug biodistribution, uptake kinetics, provide support for development of new contrast agents based on targeted nanoparticles, and importantly, affects of nanomaterial drug delivery on disease outcomes.